Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYL040012 in Open-angle Glaucoma or Ocular Hypertension
NCT02250612Phase 2Completed
- Sponsor
- Sylentis
- Start
- Oct 2014
- Primary completion
- Aug 2015
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of bamosiran in open-angle glaucoma (OAG) and ocular hypertension (5 arms), sponsored by Sylentis. Primary endpoint: Change From Baseline in the Mean Diurnal IOP at Day 28. Started Oct 2014; status: completed.
02
Drugs
bamosiran
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT02250612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02250612.